|
1
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong
Z, Lu S, Cheng Y, Han B, Chen L, et al: First-line erlotinib versus
gemcitabine/cisplatin in patients with advanced EGFR
mutation-positive non-small-cell lung cancer: Analyses from the
phase III, randomized, open-label, ENSURE study. Ann Oncol.
26:1883–1889. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paz-Ares L, Tan EH, O'Byrne K, Zhang L,
Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, et al: Afatinib
versus gefitinib in patients with EGFR mutation-positive advanced
non-small-cell lung cancer: Overall survival data from the phase
IIb LUX-Lung 7 trial. Ann Oncol. 28:270–277. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kato T, Yoshioka H, Okamoto I, Yokoyama A,
Hida T, Seto T, Kiura K, Massey D, Seki Y and Yamamoto N: Afatinib
versus cisplatin plus pemetrexed in Japanese patients with advanced
non-small cell lung cancer harboring activating EGFR mutations:
Subgroup analysis of LUX-Lung 3. Cancer Sci. 106:1202–1211. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oizumi S, Kobayashi K, Inoue A, Maemondo
M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga
S, et al: Quality of life with gefitinib in patients with
EGFR-mutated non-small cell lung cancer: Quality of life analysis
of North East Japan Study Group 002 Trial. Oncologist. 17:863–870.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Inoue A, Kobayashi K, Maemondo M, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Updated overall survival
results from a randomized phase III trial comparing gefitinib with
carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer
with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 24:54–59.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
PROFILE 1014 Investigators: First-line crizotinib versus
chemotherapy in ALK-positive lung cancer. N Engl J Med.
371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus Docetaxel in Advanced
Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell
Lung Cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
The Japan Lung Cancer Society: https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3April
6–2018
|
|
15
|
Meropol NJ, Schrag D, Smith TJ, Mulvey TM,
Langdon RM Jr, Blum D, Ubel PA and Schnipper LE; American Society
of Clinical Oncology: American Society of Clinical Oncology
guidance statement: The cost of cancer care. J Clin Oncol.
27:3868–3874. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Williams I, McIver S, Moore D and Bryan S:
The use of economic evaluations in NHS decision-making: A review
and empirical investigation. Health Technol Assess. 12(iii): ix–x,
1-175. 2008.
|
|
17
|
Ting J, Tien Ho P, Xiang P, Sugay A,
Abdel-Sattar M and Wilson L: Cost-Effectiveness and Value of
Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for
First-Line Treatment of Advanced EGFR Mutation-Positive
Non-Small-Cell Lung Cancer in the United States. Value Health.
18:774–782. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pharmaceutical Society: Insurance drug
encyclopedia, Jiho. Pharmaceutical Society; Tokyo; 2012
|
|
19
|
Kawakami Y: Medical fee points table. 35th
edition. Social Insurance Institute; Tokyo; 2008
|
|
20
|
US Department Of Health And Human
Services: Common terminology criteria for adverse events (CTCAE)
version 4.0. United States, National Cancer Institute. 2009,
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40April
6–2018
|
|
21
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shiroiwa T, Sung YK, Fukuda T, Lang HC,
Bae SC and Tsutani K: International survey on willingness-to-pay
(WTP) for one additional QALY gained: What is the threshold of cost
effectiveness? Health Econ. 19:422–437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohkusa Y and Sugawara T: Research for
Willingness to Pay for One QALY Gain. Iryo To Shakai. 16:157–165.
2006.(In Japanese). View Article : Google Scholar
|
|
24
|
Takeda M, Okamoto I and Nakagawa K: Pooled
safety analysis of EGFR-TKI treatment for EGFR mutation-positive
non-small cell lung cancer. Lung Cancer. 88:74–79. 2015. View Article : Google Scholar : PubMed/NCBI
|
